US 11292835
Low dose antibody-based methods for treating hematologic malignancies
granted A61KA61K2039/505A61K51/1069
Quick answer
US patent 11292835 (Low dose antibody-based methods for treating hematologic malignancies) held by Actinium Phamaceuticals, Inc. expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Actinium Phamaceuticals, Inc.
- Grant date
- Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K51/1069, A61K51/1093, A61K51/1096